Federal authorities are investigating the death of another child who is believed to have died after eating Abbott Laboratories baby formula
Food and Drug Administration (FDA) officials said an investigation into the circumstances of a baby who died in January has been launched.
They said the FDA was notified of the death on June 10.
Abbott initiated a recall of its infant formula products and closed its Michigan plant in February following reports of serious bacterial infections in four infants.
Two of them died, and the FDA said it hadn’t been able to show conclusively whether Abbott’s formula was the cause of the illnesses or deaths. The company said there was no evidence its formula was linked to the illnesses or deaths.
In any case, the move exacerbated a shortage at several manufacturers that began with pandemic supply chain problems, and led to criticism of the Biden administration for being slow to acknowledge and respond to the problem.
In the end, the President enacted the Defense Production Act, which gives the government more control over industrial production in emergencies, to direct formula ingredient suppliers to prioritize delivery to formula makers.
He also founded Operation Fly Formula, which instructed the Department of Health and Human Services to import formulas from overseas. At least six countries helped deliver relief supplies.
In a statement, the agency said: “The investigation into this latest consumer complaint is in its early stages and the agency will provide an update as soon as it learns more.”
It said the agency previously reported its review of complaints related to nine infant deaths.
Only two have been linked to the investigation of Abbott Nutrition’s Sturgis plant, and despite extensive investigation, the evidence does not rule out or rule out a definitive link between these infant deaths and the product manufactured at Abbott Nutrition’s Sturgis plant.
“The FDA works day and night to ensure parents and caregivers can easily find safe and nutritious formula products for any child who needs them,” said FDA Commissioner Robert Califf.
“I’ve spoken personally to infant formula manufacturers over the past few weeks and all have significantly ramped up their production efforts, resulting in more supplies becoming available on store shelves in the future.”
In a statement to The Independent, Abbott said, “The FDA notified Abbott of this case last week, but limited product and clinical information was made available to evaluate the case.”
It added: “At this time there are no conclusions that can be drawn and no evidence to suggest a causal relationship between Abbott’s formulas and this reported case. If additional information is available, we will investigate further in accordance with our complaints handling process.”